3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
2
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
8
Neoplasms
4
Neoplasm Metastasis
3
Lung Neoplasms
3
Hematologic Neoplasms
3
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Lymphoproliferative Disorders
2
Lymphoma, Large-Cell, Anaplastic
2
Sexual Dysfunction, Physiological
1
Rare Tumor
1
Neuroblastoma
1
Lymphoma
1
Lung Diseases
1
Eunuchism
1
Erectile Dysfunction
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Brain Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
23
Radiosurgery
21
Temozolomide
14
Bevacizumab
11
pembrolizumab
10
Specimen Handling
9
Nivolumab
8
Radiotherapy
7
Ipilimumab
7
Magnetic Resonance Imaging
6
Cyclophosphamide
5
Capecitabine
5
Blood Specimen Collection
5
encorafenib
4
Radiation
4
Neuropsychological Tests
4
Mental Status and Dementia Tests
4
Memantine
4
Carboplatin
4
fludarabine
3
fluciclovine F-18
3
binimetinib
3
abemaciclib
3
Watchful Waiting
3
Proton Therapy
3
Etoposide
3
Dexamethasone
3
Adrenal Cortex Hormones
3
trastuzumab deruxtecan
2
sacituzumab govitecan
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Brain Neoplasms
×
alectinib
×
Clear all
NCT05987644
2026-04-08
DURABLE
Hoosier Cancer Research Network
Phase 1/2
Recruiting
56 enrolled